China

The company officially listed on the Hong Kong Stock Exchange on June 5, achieving a market valuation of approximately HK$10.7 billion (US$1.37 billion) following its debut.

I-MED operates a network of 215 clinics across Australia and New Zealand and performs more than seven million patient procedures annually.

The product will be manufactured and commercialized to support treatment and prevention needs during influenza seasons, with an emphasis on improving availability for younger patients across China.

Since December 2025, CBC Group, together with the company’s directors have cumulatively purchased more than 3.062 million shares in the open market, amounting to over HK$113.8 million (US$14.56 million).

CTTQ will also purchase a supply of bepirovirsen for an initial period of five and a half years, while GSK will record product sales from the arrangement, though the companies are not disclosing the financial value of the deal.

Hengrui will oversee the initial human clinical studies for the immunology assets licensed from BMS, a move intended to speed up proof-of-concept data generation.

Biogen now holds worldwide rights to the investigational therapy, felzartamab, which is currently undergoing Phase 3 clinical trials for several immune-mediated diseases.

Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, and Qiming Venture Partners co-led the financing initiative.

The donation includes a hydraulic integrated operating table, a stainless steel instrument table, a manual wheelchair, and a surgical operating lamp.

This shift applies to all three Merck vaccines distributed by Zhifei: Gardasil, the rotavirus vaccine RotaTeq, and the pneumococcal vaccine Pneumovax 23.